Bao’s study (Bao et al., 2018) showed the CR rate (61.7% vs. 48.7%) and 3-year OS rate (35.3% vs. 26.8%) were better in the CLAG (CLAD+ Ara-C +G-CSF) chemotherapy group than those in the FLAG(FLU + Ara-C + G-CSF) group for 103 patients with refractory relapsed AML. This evidence concerns the gene CSF3 and acute myeloid leukemia.